ketoprofen Side Effects
Also known as: Orudis
Analysis of 12,302 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
12,302
Death-Related
1,136
9.2% of reports
Hospitalizations
6,176
50.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,136 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| PYREXIA | 174 |
| OVERDOSE | 165 |
| CONSTIPATION | 148 |
| PAIN | 147 |
| DRUG INEFFECTIVE | 144 |
| RASH | 143 |
| OFF LABEL USE | 136 |
| FATIGUE | 135 |
| DEATH | 134 |
| HYPERHIDROSIS | 130 |
| HYPERTENSION | 130 |
| HEADACHE | 129 |
| FOETAL DEATH | 124 |
| THROMBOCYTOPENIA | 124 |
| FLUID RETENTION | 123 |
| INTENTIONAL PRODUCT MISUSE | 123 |
| BACK PAIN | 122 |
| DRUG INTOLERANCE | 120 |
| IMMUNODEFICIENCY | 120 |
| PSORIASIS | 118 |
Reactions in Hospitalization Reports
Top reactions in 6,176 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ACUTE KIDNEY INJURY | 407 |
| VOMITING | 392 |
| NAUSEA | 333 |
| DIARRHOEA | 316 |
| DRUG INTERACTION | 309 |
| PYREXIA | 308 |
| DYSPNOEA | 274 |
| DRUG INEFFECTIVE | 270 |
| PAIN | 270 |
| HEADACHE | 264 |
| ASTHENIA | 251 |
| FATIGUE | 229 |
| PNEUMONIA | 209 |
| ANAEMIA | 208 |
| ABDOMINAL PAIN | 207 |
| CONDITION AGGRAVATED | 207 |
| HYPOTENSION | 188 |
| ARTHRALGIA | 183 |
| MALAISE | 175 |
| RASH | 175 |
Nearby — Related Medications
What the FAERS Data Reveals About ketoprofen Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 12,302 voluntary reports linked to ketoprofen and its brand equivalents (Orudis), spanning 2003 through 2025. Of those, 1,136 (9.2%) listed death as an outcome and 6,176 (50.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 63% were female and 37% male; age distribution skews toward 45-64, with 3,316 reports in that bracket. The single most reported reaction is headache with 1,152 submissions, followed by pain and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.